miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma by Tejero Villalba, Rut et al.
miR-141 and miR-200c as Markers of Overall Survival in
Early Stage Non-Small Cell Lung Cancer Adenocarcinoma
Rut Tejero1., Alfons Navarro1*., Marc Campayo2, Nuria Viñolas2, Ramon M. Marrades3, Anna Cordeiro1,
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Abstract
Background: Several treatments in non-small cell lung cancer (NSCLC) are histology-dependent, and the need for histology-
related markers is increasing. MicroRNAs (miRNAs) are promising molecular markers in multiple cancers and show
differences in expression depending on histological subtype. The miRNA family miR-200 has been associated with the
regulation of epithelial-mesenchymal (EMT)/mesenchymal-epithelial transition (MET). EMT involves profound phenotypic
changes that include the loss of cell-cell adhesion, the loss of cell polarity, and the acquisition of migratory and invasive
properties that facilitates metastasis. A dual role for the miR-200 family in the prognosis of several tumors has been related
to tumor cell origin. However, the prognostic role and function of miR-200 family in early-stage NSCLC adenocarcinoma and
squamous cell carcinoma (SCC) have not been well established.
Methods: miRNA expression was determined using TaqMan assays in 155 tumors from resected NSCLC patients. Functional
studies were conducted in three NSCLC cell lines: H23, A-549 and HCC-44.
Results: High miR-200c expression was associated with shorter overall survival (OS) in the entire cohort (p = 0.024). High
miR-200c (p = 0.0004) and miR-141 (p = 0.009) expression correlated with shorter OS in adenocarcinoma – but not in SCC. In
the multivariate analysis, a risk score based on miR-141 and miR-200c expression emerged as an independent prognostic
factor for OS in the entire cohort (OR, 2.787; p = 0.033) and in adenocarcinoma patients (OR, 10.649; p = 0.002). Functional
analyses showed that miR-200c, was related to mesenchymal-epithelial transition (MET) and affected cell migration and E-
cadherin levels, while overexpression of miR-141 reduced KLF6 protein levels and produced an increase of secretion of
VEGFA in vitro (H23, p = 0.04; A-549, p = 0.03; HCC-44, p = 0.02) and was associated with higher blood microvessel density in
patient tumor samples (p,0.001).
Conclusion: High miR-141 and miR-200c expression are associated with shorter OS in NSCLC patients with adenocarcinoma
through MET and angiogenesis.
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Introduction
Lung cancer is the most common cause of cancer death, with
more than 226,000 new cases in the United States in 2012 [1].
Eighty percent of lung cancers are non-small-cell lung cancer
(NSCLC) [2], which has a 5-year survival of only 10% overall and
60–70% in stage I patients, highlighting the need for novel
diagnostic and therapeutic strategies. Surgical resection, when
possible, remains the only curative treatment for early-stage
NSCLC. However, nearly 50% of resected patients experience
recurrence and have a dismal prognosis [2]. Several novel
treatments in NSCLC are histology-dependent, and squamous
cell carcinoma (SCC) responds somewhat differently than adeno-
carcinoma to certain treatment regimens[3,4] [5]. However, few
histology-dependent prognostic biomarkers are available for
routine use in clinical practice, especially in resectable patients.
In recent years, microRNAs (miRNAs) have emerged as
promising molecular markers in multiple cancers, including
NSCLC [6]. Specific miRNAs have been described as histology-
specific prognostic markers for SCC (miR-146b and miR-155) [7]
or adenocarcinoma (miR-21) [8].
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The miR-200 family is composed of five members located in
two different clusters: miR-200a, miR-200b and miR-429
comprise cluster 1(chromosome 1), and miR-200c and miR-141
comprise cluster 2 (chromosome 12). All five miRNAs have been
associated with the regulation of epithelial-mesenchymal (EMT)/
mesenchymal-epithelial transition (MET) [9]. EMT involves
profound phenotypic changes that include the loss of cell-cell
adhesion, the loss of cell polarity, and the acquisition of migratory
and invasive properties [10]. This process is fundamental for
embryonic development and is also involved in tumor invasion
and metastasis [11]. The miR-200 family act through their targets
ZEB1 and ZEB2 [9] and TGF-b2 [12]. The miRNAs are thus
able to enforce the epithelial phenotype through post-transcrip-
tional repression of these genes, allowing the expression of E-
cadherin and of polarity factors necessary for the formation of cell-
cell junctions. The miR-200 family seems to have a dual role in
patient prognosis. Overexpression of the miR-200 family acts as a
marker of better outcome in gastric and ovarian cancers
[13,14,15]. In breast cancer [16] and NSCLC [17] in contrast,
high expression of the miR-200 family is associated with shorter
survival. In breast cancer, the miR-200 family promotes metastasis
through an non-E-cadherin-related mechanism, targeting
SEC23A, which mediates secretion of metastasis-suppressive
proteins[16]. However, the role of high miR-200 levels in NSCLC
has not yet been elucidated.
In the present work, we have analyzed the role of members of
the miR-200 family in tumors from resected NSCLC patients and
correlated our findings with overall survival (OS) after surgery,
both in the entire cohort and according to histological subtypes. In
addition, we have studied the functional implications of the
prognostic markers in NSCLC cell lines.
Results
Patients
Table 1 shows the main clinical characteristics for all 155
patients. Median age was 65 years (range, 35–85) and 87% were
males. Twenty-one (13.6%) patients had Eastern Cooperative
Oncology Group (ECOG) performance status (PS) 0, and 132
(85.2%) had PS 1. Ninety-four (60.6%) patients had stage I disease.
Seventy-three (47.1%) patients had adenocarcinoma and 70
(45.1%) SCC. One hundred and thirty-eight (89%) patients were
current or former smokers. Twenty (12.9%) patients received
adjuvant chemotherapy (16 for stage II or III disease and four for
stage I disease with T.4 cm). Median follow-up was 43 months
(range, 2-160). After a follow-up of 160 months, 70 (45.2%)
patients had relapsed.
Table 1. Main patient characteristics.
Characteristic Value N = 155, N (%)
Sex Male 135 (87)
Female 20 (13)
Age #65 74 (47.8)
.65 81 (52.2)
ECOG Performance Status 0 21 (13.6)
1 132 (85.2)
2 2 (1.2)
Disease Stage I 94 (60.6)
II 34 (22)
III 27 (17.4)
Histology Adenocarcinoma 73 (47.1)
Squamous cell carcinoma 70 (45.1)
Others 12 (7.8)
Smoking History Current smoker 61 (39.3)
Former smoker 77 (49.7)
Never smoker 9 (5.8)
Unknown 8 (5.2)
Type of Surgery Lobectomy/Bilobectomy 121 (78.1)
Pneumonectomy 25 (16.1)
Atypical resection 9 (5.8)
Adjuvant Chemotherapy Yes 20 (12.9)
No 135 (87.1)
Recurrence No 85 (54.8)
Yes 70 (45.2)
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miR-200 family expression and clinical characteristics
Paired tumor and normal tissue samples were obtained from
155 NSCLC patients. The five members of miR-200 are found in
two clusters: miR-200a/b, and miR-429 (cluster 1) and miR-200c
and miR-141 (cluster 2). All members of the miR-200 family,
except miR-141, were downregulated in tumor compared to
normal tissue (miR-200a, p = 0.043; miR-200b, p,0.001; miR-
429, p = 0.003; miR-200c, p,0.001) (Figure S1).
Patients with PS 1-2 showed higher levels of miR-429
(p = 0.039) than those with PS 0. Current smokers had lower
levels of miR-200a (p = 0.027) and miR-429 (p = 0.032) than
never-smokers or former smokers.
miR-141 and miR-200c as markers of OS
Using the cutoffs defined by the Maxstat package of R, we
classified patients as having high or low expression levels of the five
miRNAs. Among the 155 patients in the entire cohort, those with
high levels of miR-200c showed a shorter OS (p = 0.024;
Figure 1A). Among the 94 patients with stage I disease, high
levels of miR-200c (p = 0.019; Figure 1B) and miR-141 (p = 0.03;
Figure 1C) were both associated with shorter OS. No significant
differences in OS were identified according to the expression levels
of the remaining miRNAs.
miR-141 and miR-200c in adenocarcinoma
No differences in OS were observed according to the expression
levels of either miR-141 or miR-200c in patients with SCC
(Figure 2A and 2B). However, among patients with adenocarci-
noma, the miRNAs identified two well-differentiated groups.
Mean OS for adenocarcinoma patients with high miR-200c
expression was 61.2 months (95% CI = 42.9–79.5), while it was
145.5 months (95% CI = 134.4–156.6) for those with low levels
(P,0.001; Figure 2C). Mean OS for adenocarcinoma patients
with high miR-141 expression was 71.7 months (95% CI = 44.9–
81.6), while it was 136.9 months (95% CI = 110.9-1162.9) for
those with low levels (p = 0.009; Figure 2D).
We then analyzed the combinatory effect of miR-141 and miR-
200c by generating a risk score based on expression levels of both
miRNAs. Patients with high levels of both miRNAs were classified
as high-risk, those with low levels of both miRNAs as low-risk, and
Figure 1. OS analysis in the entire cohort. OS according to (A) miR-200c expression levels in the entire cohort (N = 155); (B) miR-200c expression
levels in stage I patients (N = 94); and (C) miR-141 expression levels in stage I patients (N = 94).
doi:10.1371/journal.pone.0101899.g001
Figure 2. OS analysis by histological subtype. Overall survival according to (A) miR-200c expression levels in patients with SCC (N = 70); (B)
miR-141 expression levels in patients with SCC (N = 70); (C) miR-200c expression levels in patients with adenocarcinoma (N = 73); and (D) miR-141
expression levels in patients with adenocarcinoma (N = 73).
doi:10.1371/journal.pone.0101899.g002
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those with other combinations as intermediate-risk. Five year OS
was 49.4% for high-risk patients, 66.7% for intermediate-risk
patients, and 100% for low-risk patients (p = 0.002; Figure 3).
miR-200c has a greater impact on cell migration than
miR-141
Cell migration was measured by in vitro scratch assay after
transfection with pre-miR-200c, pre-miR-141 or pre-miRNA
negative control. High levels of miR-200c reduced cell migration
in comparison with control in the H23 cell line (p = 0.005), A-549
(p = 0.0085) and HCC-44 (p = 0.013) (Figure 4A). No significant
differences were observed for miR-141, except in A-549
(p = 0.043). After transfection, E-cadherin levels were analyzed
by immunohistochemistry (Figure 4B) and increased levels were
observed in cells transfected with pre-miR-200c.
miR-141 negatively regulates KLF6, leading to increased
VEGFA levels in vitro, and is related to higher microvessel
density in patient samples
Since miR-141 overexpression had previously been related to
higher blood vessel formation in ovarian tumors of mouse models
[18], we examined the potential impact of this mechanism on the
prognostic role of miR-141 in NSCLC. Using TargetScan 6.2, we
identified KLF6 as a putative target of miR-141 but not of miR-
200c. Immunoblotting of KLF6 in H23 cells transfected with pre-
miR-141or pre-miR-200c showed that only miR-141 significantly
reduced the KLF6 protein levels at 24 h (Figure 5A). Since KLF6
regulates the expression and secretion of VEGFA, a critical
angiogenic factor [19], we examined the effect of increasing miR-
141 expression levels on VEGFA levels. We overexpressed both
miR-141 and miR-200c in the H23, A-549 and HCC-44 NSCLC
cell lines and treated the cells with DFX to produce hypoxia. After
48 hours, we analyzed the protein levels of VEGFA in the
supernatant of these cells. The overexpression of miR-141
produced a mean increase of 28% in release of VEGFA (H23,
p = 0.04; A-549, p = 0.03, HCC-44, p = 0.02), while no significant
differences were observed for miR-200c, except in the HCC-44
cell line (p = 0.04) (Figure 5B).
We then sought to determine if there exists a relation between
miR-141 expression levels and the number of blood vessels in
patient samples. After determining the number of blood vessels in
tumor samples from 29 patients by immunohistochemistry, using
an antibody against CD34+, which is a marker of the blood vessel
endothelium (Figure 5C), we classified the tumor samples in two
groups: high or low levels of miR-141. The mean number of blood
vessels in tumors with high levels was 22% higher than the mean
in tumors with low levels (P,0.001; Figure 5D).
Multivariate analyses
In the multivariate analysis in the entire cohort, we included all
the clinical and biological factors with univariate P#0.1 and the
risk score based on miR-141 and miR-200c expression. The miR-
141/miR-200c risk score (high-risk vs others) emerged as an
independent prognostic marker of shorter OS (OR, 2.787; 95%
CI = 1.087-7.148; p = 0.033), together with stage . I and age .65
(Table 2).
In the multivariate analysis including only adenocarcinoma
patients, the miR-141/miR-200c risk score was also an indepen-
dent prognostic factor for OS (OR, 10.649; 95% CI = 2.433–
46.608; p = 0.002) together with age .65 (Table 2).
Discussion
In the present work, we have found that high miR-141 and
miR-200c expression are associated with shorter survival in
resected NSCLC adenocarcinoma patients, including those with
early-stage disease. Moreover, the combinatory effect of the two
miRNAs was an independent prognostic factor for OS. Different
mechanisms are involved in the effect of these miRNAs; while
miR-141 seems to act through angiogenesis by inhibiting KLF6
and increasing VEGFA levels, miR-200c plays a role in the
regulation of MET.
Recently, a phenotypic plasticity has been postulated for
transient EMT-MET processes [20]. Induction of MET by
overexpression of miR-200 family members is important at a
later point in the metastasis process. While EMT allows the cell to
migrate from the primary tumor, MET enables it to colonize and
produce metastases in distant organs [10,11]. Thus, both
downregulation and overexpression of miR-200 family members
have been related to worse prognosis. In order to investigate if the
regulation of MET by miR-141 and miR-200c was histology-
dependent, we examined their prognostic value in the two major
histological subtypes and found both miR-141 and miR-200c were
related to OS only in adenocarcinoma patients. It has been
observed that NSCLC adenocarcinoma is a more mesenchymal-
like tumor type, since it has been observed that vimentin, a marker
of mesenchymal cells, was overexpressed in well differentiated
adenocarcinomas and in the H23, A-549 and HCC-44 cell lines,
but not detected in SCC tissues [21,22]. In line with our results,
miR-200c overexpression as a marker of poor prognosis was
previously reported in a cohort of 70 NSCLC patients comprised
of both adenocarcinoma and SCC histologies [17], but its
prognostic value was not examined in the subgroup of patients
with adenocarcinoma. In other tumor models, such as breast
cancer, overexpression of miR-200 family members led to
increased metastasis [23] and is associated with poor prognosis
[16]. In addition, high serum levels of miR-141 have been
associated with poor prognosis in colon cancer [24] and high levels
of miR-200c with poor prognosis in gastric cancer [25]. In
contrast, a work using data from an online TCGA database
Figure 3. OS in 73 patients with adenocarcinoma according to
the miR-141/miR-200c risk score.
doi:10.1371/journal.pone.0101899.g003
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reported that low levels of miR-200b*, miR-200a and miR-429
were related to shorter OS in a heterogeneous cohort of NSCLC
patients that included those with metastatic disease [26].
Since miRNAs modulate the levels of multiple target proteins
depending on their sequence, their effect is dependent on the
proteins expressed in each cellular type [27]. Both miR-141 and
miR-200c are located in the same chromosomal region (12p13.31)
and share the same transcription starting site [28], but if we group
the miRNAs of the miR-200 family according to the similarity of
their seed sequence, we can identify two different clusters – miR-
200bc/429 and miR-200a/141 – which are differentiated by a
single nucleotide change [29]. Although miR-141 and miR-200c
are transcriptionally regulated in the same way, they differ in their
targets. When we analyzed the role of miR-141 and miR-200c in
EMT/MET in the H23, A-549 and HCC-44 cell lines, only miR-
200c influenced EMT in all three cell lines. Overexpression of
miR-200c increased the protein levels of E-cadherin and reduced
the migration capacity of the tumor cells, as was previously shown
by Ceppi et al in a different panel of NSCLC cell lines. Ceppi et al
investigated the expression of miR-200c in vitro and in vivo and a
strong inverse correlation with invasion was detected. Reintro-
duction of miR-200c into highly invasive/aggressive NSCLC cells
induced a loss of the mesenchymal phenotype by restoring E-
cadherin and reducing N-cadherin expression, and inhibited in
vitro cell invasion as well as in vivo metastasis formation [30].
Moreover, Pacurari et al. found that miR-200c downregulation in
SCC lung tumor samples was correlated with increased levels of
DCL1, ATRX and HFE – biomarkers related to EMT [31].
Although miR-141 is a mir-200 family member, it was not
involved in EMT/MET. The in vitro overexpression of miR-141
was related to reduction of KLF6 protein levels, producing an
increase in the secretion of VEGFA. Moreover, tumors with high
levels of miR-141 had a higher number of blood vessels. It has
been shown that cancer-associated fibroblasts (CAFs) isolated from
Figure 4. Overexpression of miR-200c affects cell migration. (A) After 36 or 48h of transfection with pre-miRNAs in the NSCLC cell lines, cell
migration was measured by in vitro scratch assay. High levels of miR-200c reduced cell migration in comparison with control in all cell lines (H23,
p = 0.005; A-549, p = 0.0085; HCC-44, p = 0.013), while high levels of miR-141 reduced cell migration only in A-549 (p = 0.04). (B) E-cadherin levels were
evaluated by immunohistochemistry and increased levels were observed in cells transfected with pre-miR-200c in comparison with those transfected
with pre-miR-141 or pre-miR-control in all three cell lines.
doi:10.1371/journal.pone.0101899.g004
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murine lung adenocarcinomas secreted abundant VEGFA and
enhanced tumor cell invasion in coculture studies [32]. When we
analyzed the expression of miR-141 in tumor and paired normal
tissue, we did not observe significant differences in expression
levels, leading us to speculate that the prognostic role of miR-141
may be related to its expression in CAF cells rather than in tumor
Figure 5. Overexpression of miR-141 negatively regulates KLF6, leading to increased VEGFA levels in vitro, and is related to higher
microvessel density in patient samples. (A) Immunoblotting of KLF6 in cells transfected with pre-miR-Negative Control or pre-miR-141/200c.
miR-141 significantly reduced KLF6 protein level in the three cell lines. (B) After 48 h of transfection with pre-miRNAs in hypoxic conditions, VEGFA
concentration in the culture supernatant was measured by ELISA. All results represent the mean 6 SEM from 3 independent experiments. (C) A total
of 29 adenocarcinoma tumor tissue sections were analyzed by immunohistochemistry with CD34+ as vessel marker; two representative cases with
high/low levels of miR-141 are shown. (D) Significant differences in blood microvessel density between adenocarcinomas with high levels of miR-141
and those with low levels of miR-141 were observed (p,0.001).
doi:10.1371/journal.pone.0101899.g005
Table 2. Multivariate analysis for OS in the entire cohort (N = 155) and in the subgroup of patients with adenocarcinoma (N = 73).
ENTIRE COHORT
OS OR (95% CI) P
Male sex 2.773 (0.949–8.100) 0.062
Stage .I 2.58 (1.178–5.494) 0.017
Age .65 2.629 (1.374–5.029) 0.003
High-risk miR-141/miR-200c score 2.787 (1.087–7.148) 0.033
ADENOCARCINOMA
OS OR (95% CI) P
Age.65 3.693 (1.420–9.601) 0.007
High-risk miR-141/miR-200c score 10.649 (2.433–46.608) 0.002
doi:10.1371/journal.pone.0101899.t002
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cells. The overexpression of miR-141 would lead to overproduc-
tion of VEGFA and increased neoangiogenesis, which have
previously been related to prognosis in NSCLC [33].
Materials and Methods
Study population and ethics statement
One hundred and fifty-five adult patients diagnosed with
NSCLC who underwent complete surgical resection at Hospital
Clinic in Barcelona, Spain between March 1996 and December
2009 were included in the study. Approval for the study was
obtained from the center’s institutional review board, and written
informed consent was obtained from each participant in accor-
dance with the Declaration of Helsinki.
RNA extraction and miRNA analysis
Total RNA and miRNA detection was performed from FFPE
tumor tissues as previously described [34]. MiRNA detection was
performed using commercial assays (TaqMan MicroRNA assays,
Appplied Biosystems).
Western Blot analysis
Western Blot analysis was performed as previously described
[35] using the following primary antibodies: KLF6 sc-7158 (Santa
Cruz Biotechonology) and a-tubulin (Sigma).
Immunohistochemistry
The immunohistochemical assay, were performed as previously
described [36] using a Flex Monoclonal Mouse Anti-Human
CD34 Class II clone QBend 10 Ready-to-Use (Dako) and
Monoclonal Mouse Anti-Human E-Cadherin Clone NCH-38
(Dako).
Blood vessel quantification
Four independent areas were selected under a 40X field, and a
200X field (0.785 mm2 per field) and used to count CD34-positive
vessels in each of these areas. Two independent pathologists
examined the slides, and the average of four 200X field counts of
CD34-positive vessels was recorded.
Cell lines, miRNA transfection and VEGF quantification
H23 (American Type Culture Collection) and HCC-44 (DSMZ)
cells were cultured in RPMI 1640 (Invitrogen) containing 10%
fetal calf serum (Invitrogen). A-549(DSMZ) cells were cultured in
DMEM (Invitrogen) containing 10% fetal calf serum.
One day before transfection, 76104 cells were seeded in 6-well
plates. The following day, cells were transfected with 100nM pre-
miR-141/200c or pre-miR-Negative Control#2 using Lipofecta-
mine 2000 (Invitrogen). At 24 h post-transfection, cells were
treated with 400 mM desferrioxamine to induce hypoxic condi-
tions. After 24 h incubation, VEGF concentration in supernatants
was measured in triplicate using the VEGF Human Elisa Kit
(ab100662, Abcam).
Cell migration analysis
Cell migration was measured by in vitro scratch assay [37]. 5*105
cells were plated in a 12-well plate one day before transfection with
pre-miRNAs. Twenty-four hours after transfection, the cell
monolayer was scraped in a straight line to create a ‘‘scratch’’
with a p100 pipet tip. The migration distance (mm) was assessed at
36 h (HCC-44) or at 48 h (H23 and A-549) after transfection using
cellSense Entry 1.7 software (Olympus).
Statistical analyses
OS was calculated from the time of surgery to the date of death
or last follow-up. Kaplan-Meier curves for OS, with their 95%
confidence intervals (CIs), were drawn and compared by means of
a log-rank test. All factors with a p-value,0.1 in the univariate
analysis were included in the Cox multivariate regression analyses
for OS.
Paired t-test was used to compare expression levels of miRNAs
between tumor tissue and paired normal tissue. Non-paired t-test
was used to compare differences between two groups. Optimal
cutoffs of miRNA expression data for OS were assessed by means
of maximally selected log-rank statistics using the Maxstat package
(R package). The applicability of these cutoffs was confirmed by
the Kaplan-Meier test. All statistical analyses were performed
using PASW Statistics v18 (SPSS) and R v2.8.1. The level of
significance was set at #0.05.
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